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Introduction
Vitamin A deficiency is an important problem in low- and 
middle-income countries.1 Although in these countries all-
cause mortality among young children (i.e. children aged 
from 6 months to 5 years) can be reduced by administering 
vitamin A supplements,2 there is little evidence that such 
supplements are beneficial among adults. In a meta-analysis of 
trials in which adults were given antioxidant supplementation, 
supplements of vitamin A (alone or combined with other 
antioxidants) were found to have either no effect on all-cause 
mortality or to increase such mortality.3 However, none of 
the data considered in the meta-analysis came from a low-
income country.
Among women of reproductive age, repeated pregnancies 
and prolonged lactation can heighten the risk of vitamin A 
deficiency.4 However, trials in which women have been 
given vitamin A supplements during pregnancy5 and in the 
postpartum period6 have shown no effect on mortality. Prior 
to the ObaapaVitA trial in Ghana,7 the published data on 
the effect of vitamin A supplementation among all women 
of reproductive age came from a single trial in Nepal.8 In the 
Nepalese study, which was known as the Nepal Nutrition 
Intervention Project Sarlahi-2 (NNIPS-2) trial, pregnancy-
related mortality was found to be 40% (95% confidence 
interval, CI: 3–63) lower in the vitamin A arm than in the 
placebo arm.8 Although cause-specific mortalities could 
not be examined in detail, there was little evidence that the 
beneficial effect of supplementation seen in Nepal was limited 
to obstetric causes of death or to pregnant women.9 Mortality 
in the “miscellaneous” category (including deaths associated 
with anaemia and asthma), direct maternal mortality and 
infection-related mortality were, respectively, 86% lower (95% 
CI: 24% lower to 97% lower), 12% lower (95% CI: 58% lower to 
81% higher) and 6% lower (95% CI: 58% lower to 105% higher) 
in the supplement arm than in the placebo arm. No data were 
presented on the effects of vitamin A supplementation on 
non-pregnancy-related mortality.
The main goal of the ObaapaVitA trial, which was set 
up in Ghana in 2000, was to evaluate the effect of weekly 
vitamin A supplementation in women of reproductive age 
on pregnancy-related mortality in an African setting, and 
to compare this with the effect on overall mortality.7 In this 
paper, we present the results of a secondary analysis of the 
effect of weekly vitamin A supplementation on cause-specific 
mortality in the ObaapaVitA trial. This appears to be the first 
time that such data from a low-income country have been 
published. The secondary analysis reported here was specified 
Objective To determine the effect of weekly low-dose vitamin A supplementation on cause-specific mortality in women of reproductive 
age in Ghana.
Methods A cluster-randomized, triple-blind, placebo-controlled trial was conducted in seven districts of the Brong Ahafo region of 
Ghana. Women aged 15–45 years who were capable of giving informed consent and intended to live in the trial area for at least 3 months 
were enrolled and randomly assigned, according to their cluster of residence, to receive oral vitamin A (7500 μg) or placebo once a week. 
Randomization was blocked, with two clusters in each fieldwork area allocated to vitamin A and two to placebo. Every 4 weeks, fieldworkers 
distributed capsules and collected data during home visits. Verbal autopsies were conducted by field supervisors and reviewed by physicians, 
who assigned a cause of death. Cause-specific mortality rates in both arms were compared by means of random-effects Poisson regression 
models to allow for the cluster randomization. Analysis was by intention-to-treat, based on cluster of residence, with women eligible for 
inclusion once they had consistently received the supplement or placebo capsules for 6 months.
Findings The analysis was based on 581 870 woman–years and 2624 deaths. Cause-specific mortality rates were found to be similar in 
the two study arms.
Conclusion Low-dose vitamin A supplements administered weekly are of no benefit in programmes to reduce mortality in women of 
childbearing age.
a Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, England.
b Department of Public Health, Academic Medical Centre, Amsterdam, Netherlands.
c Kintampo Health Research Centre, Ministry of Health, Kintampo, Ghana.
d School of Paediatrics and Child Health, University of Western Australia, Perth, Australia.
e Wales Cancer Trials Unit, Cardiff University, Cardiff, Wales.
f Institute of Child Health, University College London, London, England.
g Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, England.
Correspondence to Lisa Hurt (e-mail: lisa.hurt@lshtm.ac.uk).
(Submitted: 24 November 2011 – Revised version received: 3 October 2012 – Accepted: 11 October 2012 – Published online: 31 October 2012 )
Bull World Health Organ 2013;91:19–27 | doi:10.2471/BLT.11.10041220
Research
Vitamin A supplementation and mortality in Ghana Lisa Hurt et al.
a priori in the ObaapaVitA analysis 
plan. It is important to determine the 
effects of vitamin A supplementation 
on all deaths in women of reproductive 
age because it is not clear whether the 
beneficial effect seen in the NNIPS-2 
trial was “specific to maternal mortality 
or part of a reduction in all cause adult 
female mortality”.9 Although several 
plausible ways in which vitamin A 
supplementation may reduce mortality 
have been suggested (e.g. reductions in 
the severity of infections and anaemia10), 
few appear to be restricted to pregnant 
women or to women who have recently 
given birth. Vitamin A supplementation 
might therefore be expected to cause 
a reduction in non-pregnancy-related 
mortality similar to the reduction seen 
in pregnancy-related mortality. In 
addition to discussing this possibility, 
we present population-based data on 
the causes of more than 3000 deaths 
among the women in the trial; such data 
from Africa are rare and often limited by 
small, selective samples.11
Methods
The ObaapaVitA trial ran between 
December 2000 and October 2008 
and was both cluster-randomized 
and placebo-controlled. The general 
methods employed in the trial have 
been published elsewhere7 and the 
protocol is available online.12 The 
analysis plan, which was approved by 
an ad hoc data monitoring and ethics 
committee before the interim analysis of 
the trial results in June 2006, included 
a description of a series of planned 
secondary analyses. These analyses were 
designed to complement the results of 
the main trial analyses and to aid in 
the interpretation of those results. They 
included an analysis of the effect of 
vitamin A supplementation on cause-
specific adult female mortality (in 
which both individual causes of death 
and groupings of such causes were 
considered).
Participants
The ObaapaVitA trial was conducted 
in seven districts in the Brong Ahafo 
region of Ghana, where subsistence 
farming and small-scale trading are 
the main sources of income. Since 17% 
of the pregnant women previously 
investigated in the study area had < 0.70 
μmol of retinol per litre of serum,13 
the study population was assumed 
to have moderate levels of vitamin A 
deficiency.14
All women aged 15–45 years who 
were capable of giving informed consent 
and intending to live in the study area 
for at least three months (including 
women who migrated into the trial 
area during the study period and girls 
in the study area who reached an age 
of 15 years during the same period) 
were eligible for enrolment in the trial. 
Fieldworkers visited all compounds in 
the study area and – using a standard 
information sheet and, if necessary, 
an interpreter – explained the trial’s 
aims and methods to the householders. 
The women who were met by the 
fieldworkers during the visits were 
encouraged to ask questions. Informed 
consent, confirmed by signature or 
thumbprint, was obtained from each of 
the women who were recruited.
Randomization and masking
The trial area was divided into clusters 
of compounds. Each fieldworker was 
responsible for four contiguous clusters 
and visited the women in a different 
cluster every week, over a 4-weekly 
cycle. A study cluster consisted of all 
of the women living in the compounds 
visited by a fieldworker in a particular 
week. Randomization was blocked, 
with two of the clusters visited by each 
fieldworker allocated to vitamin A 
supplementation and two allocated to 
placebo. An independent statistician 
prepared  a  computer-generated 
randomization list. All staff members 
and participants were blind to treatment 
assignment throughout the trial.
Interventions
Women were randomly assigned, 
according to their cluster, to receive a 
vial containing either four vitamin A 
capsules or four placebo capsules every 
4 weeks, with instructions to take one 
capsule each week. Adherence was 
supported by an information, education 
and communication programme, based 
on formative research before the trial.15 
Each vitamin A capsule contained 
25 000 IU of retinol (7500 μg or retinol 
equivalents) in soybean oil in a dark 
red opaque soft gel; this dose delivered 
the recommended dietary allowance 
and was safe during pregnancy.14 
The placebo capsules only contained 
soybean oil but looked and tasted 
identical to the vitamin A capsules. 
Capsule distribution, which was phased 
by district, began between December 
2000 and January 2003 and ended in 
September 2008. Data collection ended 
four weeks after the last capsule had 
been distributed.
Data collection
Data on pregnancies, births, deaths, 
migrations,  hospital  admissions, 
m o r b i d i t y,  s o c i o d e m o g r a p h i c 
characteristics and number of capsules 
taken were collected by the fieldworkers 
during the 4-weekly home visits. Each 
week, adherence was also assessed in detail 
(including observation of capsule vials) 
among a random sample of 10 women 
from each of four different clusters. For 
this, the four clusters were selected so that 
there was one cluster each from among 
those where each study subject should 
have had three, two, one and no capsules 
remaining in her vial. A sub-study, 
consisting of a random sample of 440 
pregnant women and 440 non-pregnant 
women, was conducted in September 
2008 to assess the vitamin A status of the 
trial population (by measuring the serum 
retinol concentrations of the women 
in the placebo arm) and to compare 
the serum retinol concentrations of the 
women in the vitamin A and placebo 
arms.
Adult female deaths were identified 
during the 4-weekly surveillance. Verbal 
autopsies were then conducted, by 
trained field supervisors, in interviews 
with close relatives and/or friends of 
the dead women. The autopsy data were 
collected using a questionnaire that was 
based on a validated instrument for adult 
deaths16 and an instrument for maternal 
deaths developed for a previous study.17 
Two physicians independently reviewed 
the data and assigned a cause and up 
to two associated conditions for each 
recorded death, using standard methods 
of coding.18 The physicians did not 
discuss the cases or the causes they had 
assigned at this stage. The cause of death 
was accepted if both physicians agreed. 
If the physicians did not agree, the data 
were reviewed by a third physician (who 
remained blind to the causes assigned by 
the previous physicians). If two of the 
three physicians who had then reviewed 
the case gave the same cause of death, 
that cause was accepted as accurate. 
If all three physicians disagreed, they 
were asked to discuss the case and either 
decide on a cause together or, if unable 
to reach consensus, to record the cause 
of death as “uncertain”.
Bull World Health Organ 2013;91:19–27 | doi:10.2471/BLT.11.100412 21
Research
Vitamin A supplementation and mortality in GhanaLisa Hurt et al.
Outcomes
All deaths among the trial participants 
were classified as pregnancy-related (i.e. 
as having occurred during pregnancy or 
within 42 days of the end of pregnancy, 
irrespective of the cause)19 or non-
pregnancy-related. Data on the causes 
of pregnancy-related deaths will be 
presented elsewhere. Non-pregnancy-
related deaths were grouped by cause 
according to the headings of the 
10th revision of the International 
Classification of Diseases (ICD-10).19 
A “signs and symptoms not classified 
elsewhere” category was included to 
allow some information on cases of 
acute abdomen, instantaneous death, 
death within 24 hours of symptom onset, 
or unattended deaths to be presented. 
Deaths whose cause was uncertain 
(with no cause identified during the 
coding process) or unknown (with no 
respondent identified for the verbal 
autopsy) were pooled, since the number 
of deaths with unknown cause was 
low. Data on infection- and anaemia-
associated deaths were analysed in detail 
because previous research has suggested 
that vitamin A can protect against such 
deaths. As in previous studies,20,21 deaths 
initially coded as being from “fever of 
unknown origin” were re-classified as 
having been caused by malaria because 
malaria is endemic in the study area.
Sample size
The sample size for the trial allowed 
for the detection of a 33% reduction 
in pregnancy-related mortality in 
the vitamin A arm with 90% power, 
a 5% significance level and a 10% 
design effect. The sample size also gave 
adequate power for the detection of a 
similar reduction in any specific cause 
of death that was at least as frequent as 
pregnancy-related deaths.
Statistical methods
Stata version 10 (StataCorp. LP, College 
Station, United States of America) and 
random-effects Poisson regression 
models (to account for the cluster-
randomized design) were used to 
compare the age- and cause-specific 
mortality rates (in deaths per 100 000 
woman–years of follow-up) recorded 
in the vitamin A and placebo arms. If a 
woman moved out of the trial area, data 
collected before that woman’s migration 
were included in the analysis, with the 
woman’s person–time censored on the 
date on which she was last seen.
All trial analyses were by intention 
to treat, based on cluster of residence. 
When women moved from one cluster 
to another during the trial, they received 
the same capsules as other women in 
their new cluster and so might change 
treatment arm. Four periods relating 
to these changes (“run in”, “carry over”, 
“lag” and “washout”) were defined 
a priori; full definitions are given 
in the trial protocol. Briefly, for the 
primary analysis, the first 6 months 
following recruitment were excluded 
to allow the full impact of vitamin A 
supplementation to become apparent 
(lag). When women changed treatment 
group, they continued to be included in 
their former group for 2 months because 
vitamin A supplementation was likely 
to have little or no effect in this period 
(run in) or because the effect of such 
supplementation would be reduced only 
marginally (carry over). The following 
4-month period was excluded, with the 
women contributing person–time again 
only 6 months after they had moved, to 
allow for a lag period or for the effect 
of vitamin A supplementation to abate 
(washout). Although biochemical data 
to define them do not exist, these periods 
were selected a priori in consultation 
with the members of the trial’s data 
monitoring and ethics committee, on the 
basis of advice from experts. A “pure” 
intention-to-treat analysis, in which 
women were excluded from the time 
when they changed treatment arm, was 
also performed.
Ethics and trial monitoring
The trial was approved by the ethics 
committees of the Ghana Health Service 
and the London School of Hygiene 
and Tropical Medicine. Conduct was 
overseen by a trial steering committee 
and by the members of the trial’s data 
monitoring and ethics committee, which 
undertook yearly blinded safety analyses 
and a full interim analysis in June 2006. 
The trial is registered with ClinicalTrials.
gov as trial NCT00211341.
Results
The trial profile is shown in Fig. 1. 
Overall, 1086 clusters (544 allocated 
Fig. 1. Flowchart showing the numbers of women recruited, withdrawing, migrating 
and included in the final analyses of data, ObaapaVitA trial, Ghana, 2000–2008
778 women withdrew
44 304 migrated out of trial area
15 178 migrated to vitamin A cluster
858 women withdrew
44 892 migrated out of trial area
14 723 migrated to placebo cluster
14 723 migrated in from vitamin A cluster
2266 moved from within trial 
(previous cluster not identified)
Full sample
338 490 woman–years
1553 all-cause female deaths
Full sample
342 480 woman–years
1583 all-cause female deaths
Contribution to trial analysis 
(excluding first 6 months in placebo group)
289 310 woman–years 1298 all-cause female deaths
Contribution to trial analysis 
(excluding first 6 months in vitamin A group)
292 560 woman–years 1326 all-cause female deaths
15 178 migrated in from placebo cluster
2315 moved from within trial 
(previous cluster not identified)
Allocated to placebo arm
542 clusters
Allocated to vitamin A arm
544 clusters
103 297 women of reproductive age recruited
50 502 at start 52 795 during trial
104 484 women of reproductive age recruited
50 689 at start 53 795 during trial
1086 clusters randomized
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to the vitamin A arm and 542 to the 
placebo arm) in 272 fieldwork areas were 
randomized. Recruitment, withdrawals 
and migration patterns were similar 
in the two arms (Fig. 1), as were the 
sociodemographic characteristics that 
were investigated.7 The 207 781 women 
who were recruited contributed 680 970 
woman–years of follow-up and 3136 
deaths. Although migration in and out 
of the study area was high, each woman 
enrolled was followed up for a mean 
of 3.3 years. The characteristics of the 
many women who migrated within the 
study area were similar to those of the 
women who migrated out of the study 
area (data not shown).
Adherence to capsule intake was 
high: 78.8% of the women given capsules 
took the expected number. In the 
placebo arm, 20 (15.4%) of the 217 
pregnant women investigated and 18 
(9.6%) of the 215 non-pregnant women 
investigated had < 0.70 μmol of retinol 
per litre of serum, confirming that 
the study population had moderate 
levels of vitamin A deficiency. Among 
the women in the vitamin A arm, the 
mean serum retinol concentration and 
prevalence of serum retinol levels of 
< 0.70 μmol per litre were similar to 
those recorded among the women in 
the placebo arm.7
Intention-to-treat analyses were 
based on 581 870 woman–years and 
2624 deaths (Fig. 1). Mortality rates 
from specific causes were similar in 
the two arms (Table 1). For example, 
infection-attributed mortality in the 
vitamin A arm was 1.04-fold (95% CI: 
0.92-fold to 1.18-fold) higher than in 
the placebo arm. Rates of death from 
uncertain or unknown cause did not 
differ significantly between the two arms 
either (Table 1). Nor were any significant 
between-arm differences recorded 
in the rates of death attributed to 
specific infections or anaemia (Table 2). 
Similar observations were made in the 
“pure” intention-to-treat analysis and 
in analyses using lag periods of 9 and 
12 months (data not shown).
The all-cause mortality rate in the 
trial population was 461 deaths per 
100 000 woman–years (Table 3). The 
causes of death in the whole sample 
(3136 deaths) were similar to those in 
the intention-to-treat sample (2624 
deaths) (data not shown). More than 
one in every two deaths occurred at 
home and only one fifth of the women 
who died had been in hospital for more 
than 2 days in the 12 months before 
their death.
The cause of death was uncertain 
(no cause identified during coding; 
n = 668) or unknown (no respondent 
identified; n = 60) for 728 (23%) of the 
3136 deaths recorded (Table 4). There 
were 375 pregnancy-related deaths 
(representing 16% of deaths once deaths 
with uncertain or unknown cause were 
excluded). The commonest causes of 
non-pregnancy-related deaths were 
infections (51%), particularly infection 
with human immunodeficiency virus 
(27%). About one in every four deaths 
was attributed to a non-infectious 
disease, most frequently circulatory (8% 
of deaths). Another 5% of deaths were 
injury-related and 3% were associated 
with “signs and symptoms not classified 
elsewhere”.
Mortality rates increased with age 
(Table 5). Rates of pregnancy-related 
mortality were highest in women aged 
25–29 years (because most pregnancies 
occurred in this age group). The youngest 
and oldest age groups suffered the 
highest numbers of deaths per 100 000 
pregnancies. Although mortality from 
most other causes tended to increase 
with age, mortality rates for several 
causes were lowest in women aged 
20–24 years.
Discussion
The ObaapaVitA trial was large and 
adherence to the supplements was 
good.7 The results indicate that low-dose 
weekly vitamin A supplementation has 
no effect on cause-specific mortality 
in women of reproductive age in rural 
Ghana. Most notably, there was no 
reduction in deaths from those causes 
against which vitamin A may have a 
plausible effect, such as infections. Given 
that the study population is deficient in 
vitamin A13 and has a high burden of 
infections,21 this apparent lack of benefit 
was unexpected, especially as vitamin A 
supplementation in children between 
the ages of 6 months and 5 years in 
similar populations has reduced all-
cause mortality and mortality from 
diarrhoeal diseases.2
The trial had adequate power 
to examine the effect of vitamin A 
supplementat ion on pregnanc y-
related deaths. It also had adequate 
power to examine the effect of such 
supplementation on rates of infection, 
as these were more common, among 
Table 1. Vitamin A supplementation and cause-specific mortality among women, 
Ghana, 2000–2008
Cause No. of deaths RR (95% CI)a
Placebo Vitamin A
All deaths 1298 1326 1.01 (0.93–1.09)
Pregnancy-relatedb 148 138 0.92 (0.73–1.16)
Non-pregnancy-related 1150 1188 1.02 (0.93–1.11)
Deaths caused by:
    All infections 512 540 1.04 (0.92–1.18)
    Neoplasms 52 45 0.86 (0.57–1.28)
    Disorders of blood and blood-forming organs 44 61 1.37 (0.93–2.02)
    Endocrine, nutritional and metabolic diseases 15 15 0.99 (0.49–2.00)
    Neuropsychiatric conditions 7 11 1.55 (0.60–4.01)
    Circulatory diseases 81 75 0.92 (0.66–1.26)
    Respiratory diseases 6 6 0.99 (0.32–3.05)
    Digestive diseases 28 29 1.03 (0.60–1.76)
    Genitourinary diseases 23 21 0.90 (0.50–1.63)
    Other known cause 2 5 2.48 (0.48–12.80)
    Signs and symptoms not classified elsewherec 39 35 0.89 (0.56–1.40)
    Injuries 55 43 0.77 (0.51–1.17)
    Uncertain or unknown cause 286 302 1.04 (0.88–1.23)
CI, confidence interval; RR, rate ratio.
a Calculated, as the mortality rate in the vitamin A arm divided by that in the placebo arm, after adjusting for 
clustering by use of random-effects models. The data come from an intention-to-treat analysis.
b All deaths during pregnancy, labour or delivery or within 42 days of pregnancy, regardless of cause
c Includes deaths associated with an acute abdomen, instantaneous deaths, deaths within 24 hours of 
symptom onset and unattended deaths.
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the causes of death, than pregnancy-
related deaths. Although it is difficult 
to draw firm conclusions on the effects 
of vitamin A supplementation on the 
less common causes of death, the 
relevant data have been included in 
this article because very little data have 
been published on the cause-specific 
effects of vitamin A supplementation 
in women of reproductive age. Our 
results are consistent with those of 
the NNIPS-2 trial in Nepal, in which 
vitamin A supplementation was also 
found to have no significant effect on 
rates of death resulting from infection 
or non-communicable diseases.8 The 
Nepalese study was, however, focused 
on pregnancy-related deaths.8
Although verbal autopsies are 
known to have limitations,22 they remain 
an important tool for assessing causes of 
death in populations where the complete 
and accurate registration of causes 
of death is not possible.23 The cause 
of death may have been misclassified 
for some cases in this trial, but the 
frequency and type of such inaccuracy 
are likely to have been similar in the two 
arms. The potential misclassification 
cannot explain why, for many causes of 
death, vitamin A supplementation was 
associated with a marginally higher 
mortality rate than that recorded in the 
placebo arm.
Verbal autopsies could not be 
conducted for just 60 of the women 
who died during the trial. Cause could 
not be ascertained for another 668 
deaths, but such failures to determine 
cause of death are not uncommon when 
only verbal autopsies are conducted. In 
another study based on verbal autopsies, 
no cause could be identified for > 20% 
of the deaths recorded in six of 12 
demographic surveillance sites.20 In the 
present trial, it is possible that vitamin A 
supplementation did significantly reduce 
rates of death attributable to a specific 
cause but that this trend was masked by 
the inclusion of such deaths among the 
“deaths with unknown cause”. However, 
we do not think that this is likely. All staff 
collecting data and coding the results 
of the verbal autopsies were blinded to 
treatment allocation, as were the study 
subjects. Hence, the lack of an identified 
cause probably reflects the limitations 
of the questionnaire used to collect the 
autopsy data22 rather than a differential 
bias in coding between the two treatment 
arms. This is supported by the fact that 
the rates of death from unknown cause 
were similar in the two arms.
The mortality patterns observed 
in the ObaapaVitA trial were broadly 
consistent with those described in the 
Global Burden of Disease (GBD) study.24 
The percentages of deaths attributed 
to neuropsychiatric, digestive and 
genitourinary causes and injuries were 
similar in the trial and the GBD study. 
However, differences were noted, in the 
specific percentages of deaths by cause, 
between the “Africa D” region defined in 
the GBD study (i.e. a region comprising 
26 countries with generally similar 
mortality rates, including Ghana) and 
the population investigated in the 
ObaapaVitA trial, in Ghana. In the trial, 
for example, mortality from maternal 
conditions, neoplasms and endocrine, 
nutritional, metabolic, circulatory and 
respiratory diseases was relatively low, 
whereas mortality from some other 
causes, such as infectious diseases and 
blood disorders, was relatively high. 
These differences may be real, both 
because of differences in the methods 
Table 2. Vitamin A supplementation and mortality among women caused by specific 
infections or anaemia, Ghana, 2000–2008
Cause No. of deaths RR (95% CI)a
Placebo arm Vitamin A arm
Infection
Malaria 21 24 1.13 (0.63–2.03)
Tuberculosis 51 63 1.22 (0.84–1.78)
Other respiratory infection 14 18 1.27 (0.63–2.57)
HIV/AIDS 258 276 1.06 (0.88–1.26)
Intestinal infection 59 48 0.80 (0.54–1.19)
Meningitis 45 38 0.84 (0.54–1.29)
Other infectionb 64 73 1·13 (0·81–1·58)
Anaemia
Haemolytic 15 25 1.65 (0.87–3.13)
Other 29 36 1.23 (0.76–1.99)
CI, confidence interval; HIV/AIDS, human immunodeficiency virus/acquired immunodeficiency syndrome; 
RR, rate ratio.
a Calculated, as the mortality rate in the vitamin A arm divided by that in the placebo arm, after adjusting for 
clustering by use of random-effects models. The data come from an intention-to-treat analysis.
b Includes hepatitis, abscess, cellulitis, rabies, tetanus, chicken pox, and septicaemia/infection of unknown 
etiology.
Table 3. Descriptive data on follow-up and deaths among the women enrolled in the 
ObaapaVitA, Ghana, 2000–2008
Parameter Valuea
Number of women 207 781
Person–years of follow-up 680 970
Number of deaths 3136
All-cause mortality rate (deaths per 100 000 person–years) 461
Number and percentage of deaths occurring:
    At home 1733 (55)
    In a heath facility 1136 (36)
    On the way to a health facility 62 (2)
    At another known locationb 114 (4)
    At an unknown location 91 (3)
    After hospitalization for:
          > 2 days in previous 12 months 660 (21)
          0–2 days in previous 12 months 2362 (75)
          Unknown period 114 (4)
    In rainy season (April–September) 1594 (51)
    In dry season (October–March) 1542 (49)
a For full sample, before applying the exclusion criteria for the intention-to-treat analysis.
b At the home of a traditional birth attendant, traditional healer or spiritual healer.
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used in the two studies and because of 
marked differences in cause-specific 
mortality rates between some of the 
countries that were grouped together to 
give the Africa D region (for example, 
the maternal mortality ratio – i.e. the 
number of maternal deaths per 100 000 
live births – is estimated to be 970 in 
Sierra Leone but only 350 in Ghana).25 
The women enrolled in the ObaapaVitA 
trial differed slightly in age from the 
women considered in the GBD study. 
Furthermore, the causes of some deaths 
in the ObaapaVitA trial were simply 
categorized as “signs and symptoms 
not classified elsewhere”, whereas the 
corresponding deaths recorded in the 
GBD study were reassigned to specific 
causes.26 The mortality rates given in 
reports on the GBD study are also 
simulated estimates based on several 
data sources (including censuses and 
surveys), whereas those reported here 
for the ObaapaVitA trial are based on 
data that were collected regularly and 
directly from the study population.
Despite the intensive approach to 
supplementation in the present trial 
(with home visits every 4 weeks and an 
ongoing information, education and 
communication campaign), the serum 
retinol concentrations of the women in the 
vitamin A arm who were tested were found 
to be very similar to those of the women 
in the placebo arm who were tested. This 
lack of effect was observed even though the 
women tested had been in the trial for a 
mean of 4.5 years when sampled and had an 
estimated compliance of > 90%.7 It therefore 
appears that the dose of vitamin A used in 
the trial, which was selected to deliver the 
recommended dietary allowance while 
also being safe during pregnancy, was not 
sufficient to improve serum retinol levels 
in the trial area.
In conclusion, low-dose vitamin A 
supplementation appears to have no 
beneficial effect on cause-specific 
mortality in women of reproductive 
age in rural Ghana. The data from the 
ObaapaVitA trial add to the body of 
evidence indicating that, in programmes 
that aim to reduce mortality, weekly, 
low-dose vitamin A supplementation 
for women has no useful role. Little is 
known about the effects of vitamin A 
s upp l e m e nt at i on  on  m or bi d i t y 
in adults; this is an area for further 
exploration because, although vitamin A 
supplementation had no apparent effect 
on deaths from those causes most likely 
to be affected by vitamin A, it remains 
Table 4. Causes of death among the women enrolled in the ObaapaVitA trial, Ghana, 
2000–2008
Cause or type of death No. of 
deaths
Percentage 
of all deaths 
(n = 3136)
Percentage of all 
deaths with known 
and certain cause 
(n = 2408)
Pregnancy-related: 375 12 16
    Direct maternal deaths 202 6 8
Infectious disease: 1240 40 51
    Malaria 54 2 2
    Tuberculosis 125 4 5
    Other respiratory infections 37 1 1
    HIV/AIDS 647 21 27
    Intestinal infection 125 4 5
    Meningitis 92 3 4
    Other infectiona 160 5 7
Neoplasm 107 3 4
Disorders of blood and blood-forming organs 114 4 5
Endocrine, nutritional and metabolic diseases 35 1 1
Neuropsychiatric conditions 21 1 1
Circulatory diseases 183 6 8
Respiratory diseases 12 < 1 < 1
Digestive diseases 66 2 3
Genitourinary diseases 48 2 2
Injuries and external causes 113 4 5
Other diseases 10 < 1 < 1
Signs and symptoms not classified elsewhere: 84 3 3
    Acute abdomen 21 < 1 < 1
    Instantaneous death 15 < 1 < 1
    Death within 24 h of symptom onset 37 1 1
    Unattended death 14 < 1 < 1
Uncertain or unknownb 728 23 –
AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus.
a Includes hepatitis, abscess, cellulitis, rabies, tetanus, chicken pox and septicaemia/infection of unknown 
etiology.
b Includes 668 deaths for which a cause could not be identified by using the information collected in the 
verbal autopsy and 60 deaths for which respondents for the verbal autopsies could not be identified.
Table 5. Age-specific all-cause and cause-specific mortality rates among women 
enrolled in the ObaapaVitA trial, Ghana, 2000–2008
Parameter Age (years)
< 20 20–24 25–29 30–34 ≥ 35
Person–years of follow-up 108 989 144 522 132 363 108 226 186 870
Deaths,a by cause:b
    All causes 315 306 483 572 585
    Pregnancy-related 49 57 73 67 37
    Infectious diseases 99 110 230 265 234
    Neoplasms 3 10 10 18 33
    Circulatory diseases 19 9 19 35 49
    Injuries 16 12 19 20 21
    Other known causes 50 44 51 56 77
    Uncertain or unknown cause 86 73 100 122 141
    Pregnancy-related deathsc 422 293 339 402 549
a Per 100 000 person–years.
b As a consequence of rounding, the rates of cause-specific mortality do not exactly equal the 
corresponding all-cause mortality rate when they are added together.
c Per 100 000 pregnancies.
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صخلم
 ةبرتج نم يوناث ليلتح :اناغ في باجنلإا نس في ءاسنلا ىدل ببسلا ةددمح تايفولا لىع أ ينماتيف تلامكم يرثأت
ObaapaVitA
 ينماتيف تلامكم نم ةيعوبسأ ةضفخنم ةعرج يرثأت ديدتح ضرغلا
.اناغ في باجنلإا نس في ءاسنلا ىدل ببسلا ةددمح تايفولا لىع أ
 ةعضاخ ،ةيمعتلا ةيثلاث ،ةيئاوشع ةيدوقنع ةبرتج ءارجإ مت ةقيرطلا
 متو  .اناغب  وفاهأ  غنورب  ميلقإ  في قطانم  عبس في لفغ ءاود  يقلتل
 تيلالاو ًاماع 45و 15  ينب نهرماعأ حواترت تيلالا ءاسنلا ليجست
 لىع  ةينلا  نيهدل  تناكو  ةيرنتسم  ةقفاوم  ميدقت  لىع  تارداق  نك
 لكشب نهنييعتو لقلأا لىع رهشأ 3 ةدلم ةبرجتلا ةقطنم في شيعلا
 مفلا قيرط نع أ ينماتيف يقلتل ،نهتماقإ ةعومجلم ًاقفو ،يئاوشع
 متو .عوبسلأا في ةدحاو ةرم  لفغ ءاود  وأ  )مارغوركيم  7500(
 نياديم لمع ةقطنم لك في ينتعوممج ينيعت عم ،ةيئاوشعلا بجح
 4  لك  ،نويناديلما  لماعلا  ماقو  .لفغلا  ءاودلل  ينتنثاو  ،أ  ينماتيفل
 .ةيلزنلما  تارايزلا  ءانثأ  تانايبلا  عجمو  تلاوسبك  عيزوتب  ،عيباسأ
 ينيناديلما  ينفشرلما  ةطساوب  يظفللا  حيشرتلا  تايلمع  ءارجإ  متو
 ءارجإ متو .ةافولا ببس اوددح نيذلا ،ءابطلأا ةطساوب اهتعجارمو
 قيرط نع ينفرطلا لاك في ببسلا ةددمح تايفولا تلادعلم ةنراقم
 ةيئاوشعلاب  حماسلل  ةيئاوشعلا  راثلآا  تاذ  نوساوب  رادحنا  جذمان
 ةعوممج  لىإ  ًادانتسا  ،جلاعلا  دصقب  ليلحتلا  ناكو  .ةيدوقنعلا
 رارمتساب نلهوصح درجمب جاردلإل تلاهؤلما ءاسنلا عم ،ةماقلإا
.رهشأ 6 ةدلم لفغلا ءاودلا وأ لمكلما تلاوسبك لىع
 ةلاح  2624و  ةنس-ةأرما  581870  لىع  ليلحتلا  دنتسا  جئاتنلا
 ةلثماتم ببسلا ةددمح تايفولا تلادعم نأ لىإ لصوتلا متو .ةافو
.ةساردلا فيرط في
 ًايعوبسأ اهيطاعت متي يتلا أ ينماتيف نم ةضفخنلما ةعرلجا جاتنتسلاا
 .باجنلإا نس في ءاسنلا ىدل تايفولا نم دلحا جمارب في ةديفم يرغ
possible that vitamin A reduces the 
morbidity resulting from the same 
conditions. ■
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摘要
对加纳育龄妇女死因别死亡率的影响：ObaapaVitA 试验的二次分析
目的 确定低剂量每周一次补充维生素A对加纳育龄妇女特
因死亡率的影响。
方法 在加纳布朗阿哈福地区的七个区进行整群随机、三盲
的安慰剂对照试验。招募能够给予知情同意并有意愿在受
试地区生活至少3 个月的15–45 岁妇女，按照其居住地的
整群将其随机分组，接受每周一次的口服维生素A（7500 
μg）或安慰剂。采用区组随机化方法，安排每个现场调
查地区的两个整群口服维生素A，两个整群口服安慰剂。
现场调查人员在每4 周一次的家庭访视过程中分发胶囊并
收集数据。口头尸检由现场监督员进行，由医生进行审核
并给出死亡原因。两个组的特因死亡率通过随机效应泊松
回归模型进行比较，以实现整群随机化。使用意向性分析
方法，以居住地整群为基础，妇女连续接受补充剂或安慰
剂胶囊6 个月即符合纳入条件。
结果 分析基于581870 妇女人年和2624 例死亡进行。发
现两个研究组的特因死亡率相似。
结论 每周控制低剂量补充维生素A的方法在降低育龄妇女
死亡率的计划中没有益处。
Résumé
Effet de la supplémentation en vitamine A sur la mortalité relative chez les femmes en âge de procréer au Ghana: une analyse 
secondaire de l’étude ObaapaVitA
Objectif Déterminer l’effet de la supplémentation hebdomadaire en 
vitamine A à faible dose sur la mortalité spécifique des femmes en âge 
de procréer au Ghana.
Méthodes Une étude randomisée, en triple aveugle, contrôlée contre 
placebo, a été menée dans sept districts de la région de Brong Ahafo 
au Ghana. Les femmes âgées de 15 à 45 ans, capables de donner un 
consentement éclairé et amenées à vivre dans la région de l’étude 
pendant au moins 3 mois, ont été incluses et il a été déterminé qu’elles 
recevraient une fois par semaine, au hasard selon leur groupe de 
résidence, de la vitamine A par voie orale (7 500 µg) ou un placebo. 
La randomisation a été fixée par deux groupes dans chaque zone 
recevant la vitamine A et deux groupes recevant le placebo. Toutes 
les 4 semaines, les agents de terrain distribuaient les capsules et 
recueillaient les données lors de visites à domicile. Des autopsies 
orales ont été effectuées par les superviseurs sur le terrain et analysées 
par des médecins, qui déterminaient la cause du décès. Les taux 
de mortalité spécifique dans les deux groupes ont été comparés à 
l’aide d’une régression de Poisson pour valider la randomisation des 
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groupes. L’analyse, basée sur l’intention de traiter, était basée sur le 
groupe de résidence, pour des femmes éligibles à l’étude ayant reçu 
les capsules de supplément ou de placebo de manière constante 
pendant 6 mois.
Résultats L’analyse s’est basée sur 581 870 années-femmes et 2624 
décès. Les taux de mortalité spécifique ont été jugés similaires dans les 
deux groupes de l’étude.
Conclusion Les suppléments en vitamine A à faible dose administrés 
hebdomadairement ne sont d’aucune utilité dans les programmes visant 
à réduire la mortalité chez les femmes en âge de procréer.
Резюме
Влияние добавок витамина А на смертность, вызванную конкретной причиной, у женщин 
репродуктивного возраста Ганы: вторичный анализ исследования ObaapaVitA
Цель Определить влияние еженедельной низкодозированной 
добавки витамина А на смертность, вызванную конкретной 
причиной, у женщин репродуктивного возраста Ганы.
Методы Было проведено кластерное рандомизированное, 
тройное слепое, контролируемое плацебо исследование в 
семи районах региона Бронг Ахафо, расположенного в Гане. В 
исследование были зачислены и распределены в произвольном 
порядке согласно своему местожительству для перорального 
приема раз в неделю витамина А (7500 мкг.) или плацебо женщины 
в возрасте от 15 до 45 лет, способные дать осознанное согласие 
и намеревавшиеся проживать в опытной зоне не менее 3-х 
месяцев. Рандомизация являлась блочной при назначении 
приема витамина А и плацебо в двух группах в каждой зоне 
исследования. Каждые 4 недели исследователи распределяли 
капсулы и производили сбор данных во время домашнего обхода. 
Опросы об обстоятельствах смерти проводились руководителями 
исследования и рассматривались врачами, определявшими 
причину смерти. Показатели смертности, вызванной конкретной 
причиной, в обоих группах сопоставлялись с помощью моделей 
регрессии Пуассона случайного воздействия для проведения 
кластерной рандомизации. Анализ проводился по принципу 
исходно назначенного лечения, с учетом местожительства, с 
участием женщин, допущенных к включению в исследование, при 
условии постоянного приема капсул с добавкой или плацебо в 
течении 6 месяцев. 
Результаты Анализ проводился на основе данных по 2624 
смертям и 581 870 пациенто-годам. Было установлено, что 
показатели смертности, вызванной конкретной причиной, 
являются схожими в двух исследуемых группах.
Вывод Добавки витамина А, назначаемые еженедельно, не 
оказывают благоприятного влияния по программам сокращения 
смертности среди женщин репродуктивного возраста.
Resumen
El efecto de los suplementos de vitamina A en la mortalidad por causas específicas de mujeres en edad reproductiva en Ghana: 
un análisis secundario del ensayo Obaapa VITA
Objetivo Determinar el efecto de la administración semanal de dosis 
bajas de vitamina A en la mortalidad por causas específicas de mujeres 
en edad reproductiva en Ghana.
Métodos Se realizó un ensayo aleatorio de grupos, triple ciego y 
controlado por placebo en siete distritos de la región de Brong Ahafo, 
en Ghana. Se inscribieron mujeres de entre 15 y 45 años de edad 
capaces de dar su consentimiento informado y que tuvieran previsto 
vivir en el área de ensayo durante al menos tres meses. De acuerdo 
con el grupo de residencia al que habían sido asignadas de forma 
aleatoria, recibieron semanalmente vitamina A por vía oral (7500 µg) 
o placebo. La distribución aleatoria se limitó en cada área de trabajo 
a dos grupos a los que se les administró vitamina A y dos grupos 
que recibieron placebo. Cada cuatro semanas, los investigadores de 
campo distribuyeron cápsulas y recogieron datos durante las visitas a 
los hogares. Las autopsias verbales realizadas por los supervisores de 
campo fueron revisadas por médicos, quienes determinaron la causa de 
la muerte. Se compararon las tasas de mortalidad por causas específicas 
de ambos brazos mediante los modelos de regresión de Poisson con 
efectos aleatorios para facilitar la distribución aleatoria de los grupos. El 
análisis fue por intención de tratar, según el grupo de residencia y con 
mujeres que cumplieron las condiciones de inclusión una vez habían 
recibido de forma constante las cápsulas de suplemento o placebo 
durante seis meses.
Resultados El análisis se basó en 581 870 años-mujer y 2624 muertes. 
Se descubrió que las tasas de mortalidad por causas específicas fueron 
similares en ambos brazos del estudio.
Conclusión Los suplementos de dosis bajas de vitamina A administrados 
semanalmente no presentan ninguna ventaja en los programas para 
reducir la mortalidad de las mujeres en edad reproductiva. 
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